Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol

PHASE2CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

AZD5423

oral inhaled

DRUG

Budesonide

oral inhaled

DRUG

Placebo

oral inhaled

Trial Locations (44)

Unknown

Research Site, Doganovo

Research Site, Plovdiv

Research Site, Sofia

Research Site, Varna

Research Site, Brest

Research Site, Marseille

Research Site, Montpellier

Research Site, Nice

Research Site, Pessac

Research Site, Balassagyarmat

Research Site, Budapest

Research Site, Deszk

Research Site, Százhalombatta

Research Site, Foggia

Research Site, Padua

Research Site, Verona

Research Site, Napoli

Research Site, Pisa

Research Site, Bialystok

Research Site, Gorzow Wlkp

Research Site, Lodz

Research Site, Proszowice

Research Site, Tarnów

Research Site, Barnaul

Research Site, Chelyabinsk

Research Site, Moscow

Research Site, Novosibirsk

Research Site, Saint Petersburg

Research Site, Vladikavkaz

Research Site, Yaroslavl

Research Site, Yekaterinburg

Research Site, Vráble

Research Site, Bratislava

Research Site, Humenné

Research Site, Košice

Research Site, Spišská Nová Ves

Research Site, Zvolen

Research Site, Donetsk

Research Site, Ivano-Frankivsk

Research Site, Kharkiv

Research Site, Kyiv

Research Site, Odesa

Research Site, Poltava

Research Site, Zaporizhzhya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY